Overview

The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2

Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Kinarus AG
Treatments:
Pioglitazone